Arbutus Biopharma Corp 8-K

What Happened
Arbutus Biopharma Corporation announced its financial results for the quarter ended March 31, 2026 by issuing a press release on May 13, 2026. The company furnished that press release with the SEC on Form 8-K under Item 2.02 (Results of Operations and Financial Condition); the press release is included as Exhibit 99.1 to the filing.

Key Details

• Filed: May 13, 2026 (Form 8-K).
• Reporting period: Quarter ended March 31, 2026 (Q1 2026).
• Disclosure type: Item 2.02 — press release announcing financial results; press release furnished as Exhibit 99.1.
• Form 8-K signed by Tuan Nguyen, Chief Financial Officer, on behalf of Arbutus Biopharma.

Why It Matters
This 8-K provides timely public disclosure that Arbutus has released its quarterly financial results; investors should review the attached press release (Exhibit 99.1) for specific figures on revenue, earnings, cash position, or operational updates. The Form 8-K itself furnishes the press release but does not replace the more detailed periodic filings (such as the quarterly report on Form 10-Q) where full financial statements and management discussion will appear. No other material events (e.g., executive changes or mergers) were reported in this filing.